Rishi Kora, MD
Nephrology · Glendale, WINPI 1053708511
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $46,906 of the $56,920 with a category attached, or 82.4%. 28 manufacturers reported payments, led by Amgen at 46.3% of the total. 2025 is the largest year on record at $19,108, more than ten times the $16 reported in 2019. Among nephrology clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 383 payments — averaging $148.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$26K
- AstraZeneca$26K
- Mallinckrodt Hospital Products Inc.$662
- GSK$349
- Novartis$345
- Vifor Pharma, Inc.$323
- plus $3K from 22 others
What the payments were for
- Speaking & faculty fees$46,90682%
- Travel & lodging$1,5433%
- Food & beverage$8,04114%
- Education$4301%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 86 | $26,373 |
| AstraZeneca(2 entities) | 76 | $26,020 |
| Mallinckrodt Hospital Products Inc. | 30 | $662 |
| GSK | 21 | $349 |
| Novartis | 19 | $345 |
| Vifor Pharma, Inc. | 16 | $323 |
| Bayer | 15 | $305 |
| ANI Pharmaceuticals, Inc. | 10 | $266 |
| Otsuka America Pharmaceutical, Inc. | 10 | $247 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $240 |
| OPKO Pharmaceuticals, LLC | 15 | $236 |
| Akebia Therapeutics Inc | 9 | $201 |
| Calliditas Therapeutics US Inc. | 9 | $193 |
| Travere Therapeutics, Inc. | 9 | $187 |
| Boehringer Ingelheim | 10 | $183 |
| Novo Nordisk | 5 | $112 |
| Ardelyx, Inc. | 4 | $109 |
| Fresenius USA Marketing, Inc. | 5 | $90 |
| Ultragenyx Pharmaceutical Inc. | 4 | $81 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $79 |
| Alnylam Pharmaceuticals Inc. | 3 | $71 |
| Sanofi | 3 | $67 |
| Lilly USA, LLC | 2 | $57 |
| Daiichi Sankyo Inc. | 2 | $43 |
| Pfizer | 2 | $32 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
| Bard Peripheral Vascular, Inc. | 1 | $16 |
| Boston Scientific | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$56,920 in reported general payments places this provider in the 95th percentile of 173 nephrology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 81 | $87,212 |
| VelphoroSucroferric Oxyhydroxide | 11 | $34,794 |
| RenvelaSevelamer Carbonate | 19 | $23,704 |
| RayaldeeCalcifediol | 16 | $19,696 |
| Tolvaptan | 11 | $18,224 |
| JardianceEmpagliflozin | 12 | $17,310 |
| LokelmaSodium Zirconium Cyclosilicate | 14 | $16,981 |
| EliquisApixaban | 18 | $13,847 |
| ProsolParenteral Amino Acid 20% No.1 | 72 | $11,774 |
| Sevelamer Carbonate | 39 | $5,769 |
| Bumetanide | 125 | $3,328 |
| Allopurinol | 394 | $3,007 |
| Midodrine Hcl | 38 | $2,041 |
| Calcium Acetate | 28 | $1,447 |
| Furosemide | 125 | $762 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $26,020 | $104,19395 claims |
| Fresenius USA Marketing, Inc.Velphoro | $90 | $34,79411 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $236 | $19,69616 claims |
| Otsuka Pharmaceutical Development & Commercialization, Inc.Tolvaptan | $79 | $18,22411 claims |
| Boehringer IngelheimJardiance | $183 | $17,31012 claims |
| PfizerEliquis | $32 | $13,84718 claims |
| Lilly USA, LLCOlanzapine | $57 | $10911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 173 nephrology providers in Wisconsin.
Other nephrology in Glendale
- Anushayanthan AlfredGlendale$8K
- Talal KhairiGlendale$6K
- Kamal AminGlendale$4K
- Lisa HallerGlendale$3K
- Stephen SieversGlendale$2K
- Kevin RegnerMilwaukee$246K
- Rosanna RanieriKenosha$84K
- Micah ChanFitchburg$80K
- Manohar AhujaMilwaukee$35K
- Ashraf El MeanawyMilwaukee$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.